SAREPTA THERAPEUTICS INC. - COMMON STOCK

Sarepta Therapeutics to Initiate Part B of MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Following Positive Interactions with FDA

27 Sep 2021 07:30:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics to Showcase Data from its Gene Therapy and RNA Platforms at World Muscle Society 2021 Virtual Congress

14 Sep 2021 07:30:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics to Present at Upcoming Investor Conferences

07 Sep 2021 15:30:05 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program

07 Sep 2021 07:30:01 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

31 Aug 2021 16:57:30 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Second Quarter 2021 Financial Results and Recent Corporate Developments

04 Aug 2021 15:05:02 By Nasdaq GlobeNewswire

Sarepta Therapeutics Executes Licensing Agreement for Gene Therapy Program from Nationwide Children’s Hospital to Treat Limb-Girdle Muscular Dystrophy Type 2A

04 Aug 2021 07:30:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

30 Jul 2021 16:42:29 By Nasdaq GlobeNewswire

Sarepta Therapeutics to Announce Second Quarter 2021 Financial Results and Recent Corporate Developments on August 4, 2021

28 Jul 2021 07:30:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

30 Jun 2021 17:40:58 By Nasdaq GlobeNewswire

Sarepta Therapeutics to Present at Upcoming Investor Conferences

03 Jun 2021 15:30:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

28 May 2021 17:55:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics’ Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy, SRP-9001, Demonstrates Robust Expression and Consistent Safety Profile Using Sarepta’s Commercial Process Material

18 May 2021 07:50:40 By Nasdaq GlobeNewswire

Sarepta Therapeutics to Share Expression and Safety Results from Study 103 (ENDEAVOR) Evaluating SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy

17 May 2021 15:05:01 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces First Quarter 2021 Financial Results and Recent Corporate Developments

05 May 2021 15:05:01 By Nasdaq GlobeNewswire

Sarepta Therapeutics to Present at Upcoming Investor Conferences

04 May 2021 15:30:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics Reports Positive Clinical Results from Phase 2 MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51

03 May 2021 07:50:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

30 Apr 2021 17:45:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics to Share Clinical Update for 30 mg/kg arm of MOMENTUM Study for SRP-5051, Its Investigational PPMO for the Treatment of Duchenne Muscular Dystrophy

30 Apr 2021 15:05:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics to Announce First Quarter 2021 Financial Results and Recent Corporate Developments on May 5, 2021

28 Apr 2021 07:30:00 By Nasdaq GlobeNewswire